Breakthrough Pain

Abstract

Breakthrough pain is a type of pain: a transient flare of severe pain that erupts against a background of otherwise stable, adequately controlled persistent pain. Most studied in cancer, it is defined by a temporal signature that makes it a distinctively cognitive problem: flares rise to peak intensity within minutes, last less than an hour, and often recur unpredictably, so the experience is dominated as much by anticipation and dread as by the sensation itself. This article develops breakthrough pain as a problem of timing and appraisal: what separates it from background pain, why its rapid, short-lived profile defeats slow oral analgesics, how the fallibility of memory for episodic pain corrupts its assessment, and why matching the pharmacokinetics of relief to the temporal shape of the flare is the central therapeutic idea.

Keywords: breakthrough pain, episodic pain, cancer pain, pain assessment, onset of relief

Cancer pain, and chronic pain more generally, is usually pictured as a steady ache that a fixed schedule of medication holds down. For most patients that picture is incomplete. On top of the controlled background, sudden severe flares erupt, reaching their worst in a few minutes and subsiding within the hour, and it is these flares, not the background, that patients most fear and that most degrade their lives (Portenoy & Hagen, 1990). The phenomenon was named breakthrough pain because it breaks through an analgesic regimen that is otherwise working. Its defining feature is temporal: a flare is over almost as fast as it arrives, which means that how a patient anticipates it, how accurately it is remembered and reported, and how quickly relief can be delivered matter more than sheer intensity. That is why a symptom of advanced disease is, at its core, a problem in the cognitive psychology of time, memory, and expectation.

What Breakthrough Pain Is

Breakthrough pain is formally a transitory exacerbation of pain that occurs on a background of otherwise stable, adequately controlled persistent pain (Davies et al., 2009). Three conditions must hold together: there is a background pain, that background is being controlled, and against it a flare erupts. The definition is therefore relational rather than absolute, a flare only counts as breakthrough pain if the baseline it interrupts is genuinely under control, which is why a patient whose background pain is untreated does not have breakthrough pain but simply uncontrolled pain (Portenoy et al., 1999). The distinction matters clinically because the two are corrected in opposite ways, one by adjusting the around-the-clock regimen and the other by adding a fast rescue dose on top of it.

The feature that makes breakthrough pain a subject for cognitive psychology rather than pharmacology alone is its temporal signature. Across studies the picture is consistent: flares reach peak intensity fast, with a median time to peak of only a few minutes, and are short-lived, with a median duration on the order of half an hour, though patients may experience several each day (Portenoy & Hagen, 1990; Mercadante et al., 2016). A pain that is severe, arrives in minutes, and is gone within the hour poses problems that a steady ache does not: it is largely over before a swallowed tablet can work, it is hard to capture in a clinic visit that happens between flares, and its unpredictability makes anticipation itself a source of suffering. The first demonstration makes the temporal signature concrete, letting the peak intensity, time to peak, and duration of a flare be varied against a controlled background so the characteristic spike of breakthrough pain can be seen against the baseline it interrupts.

Breakthrough pain is common wherever persistent pain is treated, though estimates vary widely with how it is defined and measured. A pooled analysis of the cancer literature put the average prevalence among patients with pain at around 60%, with individual studies ranging from roughly 40% to 80% depending on setting and criteria (Deandrea et al., 2014). That variability is not noise; it reflects a genuine difficulty of definition and assessment that has dogged the field since the phenomenon was first described, and which the rest of this article treats as central rather than incidental.

Kinds of Breakthrough Pain

Breakthrough pain is not one thing, and its subtypes differ in exactly the property that matters most for managing it: predictability. The primary division is between incident and spontaneous pain (Davies et al., 2009). Incident pain, also called precipitated pain, is brought on by an identifiable trigger, and it subdivides further by how controllable that trigger is. Volitional incident pain follows a voluntary act such as walking or standing, and because the patient chooses when to perform the act, it is the most predictable and the most amenable to pre-emptive dosing. Non-volitional incident pain follows an involuntary event such as coughing or a bowel movement, which is triggered but not scheduled. Procedural incident pain is a special case tied to an intervention such as wound dressing, predictable in timing because the clinician controls it (Haugen et al., 2010).

Spontaneous pain, sometimes called idiopathic pain, has no identifiable trigger at all. It arrives without warning, which makes it the hardest subtype to manage, because there is no event to dose ahead of and nothing to avoid, so the patient can only react after the flare has begun (Mercadante & Portenoy, 2021). This unpredictability is precisely what turns spontaneous breakthrough pain into a psychological burden as much as a sensory one: a pain that can strike at any moment breeds a background of anticipatory anxiety that a predictable pain does not.

A third entity is often discussed alongside these but is properly kept separate. End-of-dose failure is the return of pain before the next scheduled dose of a background analgesic is due, a sign that the around-the-clock regimen is under-dosed rather than that a true flare has broken through adequate control. Because its remedy is to adjust the baseline regimen rather than to add rescue medication, most consensus definitions exclude it from breakthrough pain proper, though patients experience it as one more unexpected surge (Mercadante et al., 2002).

Assessing Breakthrough Pain

The great practical obstacle to studying and treating breakthrough pain is that it is hard to measure, and the difficulty is largely cognitive. A flare is a brief event, usually past by the time a patient reaches a clinic, so almost all clinical information about it comes from memory, and memory for pain is systematically distorted. People do not average their moment-to-moment experience when they recall an episode; they reconstruct it, and the reconstruction is dominated by the most intense moment and the final moment while the length of the episode is largely ignored, the peak-end pattern with duration neglect that Redelmeier and Kahneman demonstrated for remembered pain, in which patients' retrospective ratings of a painful procedure tracked its peak and final moments rather than its total course (Redelmeier & Kahneman, 1996). This is why a report of remembered pain biases away from its true time course, a distortion that matters acutely for a symptom defined by its temporal profile (Raja et al., 2020). For a symptom that is defined by its temporal profile, this is a serious problem: a retrospective report of how bad the flares were last week is not a faithful summary of them but a memory-weighted caricature, typically inflating peaks and neglecting how brief the episodes were. The second demonstration makes this concrete, generating a day of momentary flare ratings and showing how an end-of-period recall, weighted toward the worst and most recent moments, diverges from the true momentary average.

The response to this measurement problem has taken two forms. The first is momentary assessment: capturing pain as it happens rather than in retrospect, using diaries and electronic prompts that sample the experience in real time and so sidestep the reconstruction bias entirely. The second is the development of dedicated, validated instruments that structure recall as carefully as possible. The Breakthrough pain Assessment Tool is the leading example, a questionnaire developed and validated specifically to characterize the frequency, severity, timing, and impact of flares in a standardized way, so that reports can be compared across patients and studies rather than left to unstructured recollection (Webber et al., 2014). Both approaches rest on the same recognition: that because breakthrough pain lives in memory by the time it is reported, how that memory is elicited is not a methodological footnote but a determinant of what the data mean (Haugen et al., 2010).

Assessment is further tangled by disagreement over the name itself. The term breakthrough pain, coined in the anglophone literature, does not translate cleanly, and different groups have used episodic pain, transient pain, and pain flare for overlapping but not identical phenomena. A European expert survey using the Delphi method sought a common terminology, and its participants leaned toward episodic pain as the broader, more neutral umbrella term, reflecting a lasting tension between a construct that is clinically intuitive and one that is precisely defined (Løhre et al., 2016). The confusion is not merely semantic: prevalence estimates and study comparisons depend on which definition is in force, which is part of why the reported prevalence ranges so widely (Deandrea et al., 2014).

The Psychology of Breakthrough Pain

What distinguishes breakthrough pain from background pain, psychologically, is that its burden is concentrated in time and in expectation. Because a flare is severe and fast, its intensity is experienced as an event with a beginning and an end rather than a state, and because it is often unpredictable, the intervals between flares are colored by the anticipation of the next one. Patients with breakthrough pain report worse mood, more anxiety, greater interference with daily activity, and lower satisfaction with their analgesia than patients whose pain is equally severe but steady, and much of that excess burden is attributable not to the flares themselves but to living in their shadow (Portenoy et al., 1999; Davies et al., 2011). The figure sets out the anatomy of a single flare and the anticipatory cycle that surrounds it, showing how the sensory event and the psychological response to its unpredictability reinforce each other.

Figure 1

The Anatomy of a Breakthrough Pain Flare

The psychological amplification runs through the same appraisal machinery that governs chronic pain generally. Pain catastrophizing, an exaggerated negative orientation toward actual or anticipated pain, is elevated in patients with breakthrough pain and predicts greater distress and interference, and its anticipatory component has particular purchase here: when the pain in question is sudden, severe, and unpredictable, the tendency to dwell on and magnify the threat of the next flare has ample material to work with (Mercadante & Portenoy, 2021). The revised International Association for the Study of Pain definition of pain, which frames pain explicitly as a sensory and emotional experience shaped by biological, psychological, and social factors, makes clear why this affective dimension is not incidental: the fear and anticipation that surround breakthrough flares are part of the pain, not a separate reaction to it (Raja et al., 2020).

Managing Breakthrough Pain

The clinical logic of treating breakthrough pain follows directly from its temporal signature, and it is a logic of matching. Because a flare rises in minutes and lasts under an hour, a useful rescue medication must act on the same timescale, and standard oral opioids do not. An immediate-release oral morphine tablet, long the default rescue drug, has an onset of meaningful relief on the order of thirty minutes or more, by which time the average flare has already peaked and begun to subside, so the drug arrives to treat a pain that is nearly gone while its effect lingers uselessly afterward (Zeppetella, 2008). This mismatch, between the pharmacokinetics of the treatment and the time course of the target, is the central problem breakthrough pain management has had to solve.

The solution has been the rapid-onset opioids, chiefly transmucosal and intranasal formulations of fentanyl, which are absorbed across the mucous membranes of the mouth or nose directly into the bloodstream and so begin to relieve pain within roughly ten to fifteen minutes, a far better match to the flare (Zeppetella & Davies, 2013). A Cochrane review of the trial evidence confirmed that these transmucosal fentanyl products relieve breakthrough cancer pain more effectively than placebo and more rapidly than oral morphine, establishing onset speed, not total dose, as the property that matters (Zeppetella & Davies, 2013). The third demonstration makes the matching problem interactive, overlaying the onset curve of a chosen rescue drug on a flare of adjustable duration and computing how much of the episode the drug actually covers.

Two further principles complicate the simple matching picture, and both are set out in the guidelines that codify breakthrough pain management. First, the dose of a rapid-onset opioid cannot be predicted from the background regimen and must be found by titration, escalating from a low starting dose until an effective one is reached, because the relationship between a patient's baseline opioid requirement and their rescue requirement turns out to be weak (Caraceni et al., 2012). Second, management must be matched to subtype as well as to timing: predictable volitional incident pain can be pre-empted by dosing before the triggering activity, whereas unpredictable spontaneous pain can only be treated reactively, which is exactly where the fastest-onset formulations earn their place (Fallon et al., 2018). Table 1 summarizes how the onset of relief of the main rescue options lines up against the temporal demand of a flare.

Worked Example

Consider the coverage that the third demonstration computes, and use it to show why onset speed rather than dose is the decisive property of a rescue drug. Model a breakthrough flare as an episode of fixed duration D during which the pain is above the level worth treating, and a rescue drug as providing meaningful relief only after its onset time T. The fraction of the flare that the drug actually covers is then coverage = (D − T) / D when T is less than D, and zero when the drug acts only after the flare is over.

Take a typical flare with a duration of D = 45 minutes. An immediate-release oral morphine tablet with an onset of T = 35 minutes covers (45 − 35) / 45 = 10 / 45 = 0.22, just 22% of the episode: the patient endures four-fifths of the flare unrelieved, and the drug is still active long after the pain has gone. Now switch to transmucosal fentanyl with an onset of T = 12 minutes. Coverage rises to (45 − 12) / 45 = 33 / 45 = 0.73, 73% of the episode, more than triple the oral tablet, achieved not with a larger dose but with a faster one.

The example makes the central claim quantitative. If the flare were long and steady, the ten-minute difference in onset would be trivial, because T would be small relative to D for either drug. It is precisely because the flare is short that onset dominates: when D is on the order of the onset times themselves, every minute of delay is a large fraction of the treatable window. Shorten the flare to D = 20 minutes and the oral tablet covers nothing at all, (20 − 35) being negative, while the fentanyl still covers (20 − 12) / 20 = 0.40. This is the arithmetic behind the guideline preference for rapid-onset opioids: the shorter and sharper the breakthrough pain, the more the choice of rescue drug is a choice about time (Zeppetella & Davies, 2013).

Discussion

The study of breakthrough pain traces an arc from recognition to definition to measurement to matched treatment, and at each stage the obstacle has been as much conceptual as pharmacological. Portenoy and Hagen's naming of the phenomenon in 1990 did the essential work of carving out a distinct entity from the undifferentiated mass of cancer pain, and it did so by fixing on the temporal feature, a transient exacerbation against a controlled background, that has organized the field ever since (Portenoy & Hagen, 1990). The subsequent history has been a series of attempts to pin down a construct that is clinically vivid but definitionally slippery, from the European consensus on episodic pain to the Delphi effort at a common terminology, and the persistence of that difficulty is why prevalence figures still range so widely and why comparing studies remains fraught (Mercadante et al., 2002; Løhre et al., 2016; Deandrea et al., 2014).

What the cognitive-psychological lens adds is an account of why breakthrough pain is disproportionately burdensome relative to its brief duration, and why it has been so hard to measure and treat. Its burden is inflated by anticipation, because an unpredictable severe flare colors the intervals between episodes with dread; its measurement is corrupted by memory, because an episode reconstructed after the fact is weighted toward its peak and its end rather than averaged faithfully; and its treatment is constrained by time, because relief must be delivered on the same rapid timescale as the flare or it misses the window entirely (Davies et al., 2011; Raja et al., 2020; Zeppetella, 2008). Each of these is a problem about how the mind handles time, expectation, and remembered experience, which is what makes a symptom of advanced disease a genuine topic for cognitive psychology rather than a purely clinical one.

Current Directions

Current work on breakthrough pain is pulled between two goals that sit in tension: sharpening the definition enough to compare studies, and capturing a phenomenon whose defining feature is its variability. The largest recent contribution is the Italian Oncologic Pain Multisetting Multicentric Survey, which characterized breakthrough pain across many centers and settings and confirmed both its high prevalence and the wide variation in its features from patient to patient, reinforcing that no single profile fits all flares (Mercadante et al., 2016). Alongside this descriptive work runs the continuing terminological debate, with the European expert consensus favoring episodic pain as a broader umbrella and pressing for standardized criteria so that the next generation of prevalence and treatment studies can be compared on common ground (Løhre et al., 2016). Mercadante and Portenoy's recent characterization of breakthrough pain as chameleonic captures the current mood precisely: a phenomenon that changes its appearance across patients, tumors, and settings, resisting the tidy categories that clinical trials require (Mercadante & Portenoy, 2021). Guideline bodies, meanwhile, have converged on the practical core, endorsing rapid-onset opioids titrated to effect and matched to subtype as the standard of care, even as the boundaries of the construct they treat remain under negotiation (Fallon et al., 2018). The open questions are therefore less about what to do for a flare than about how to define, measure, and predict the flares themselves, which is where the cognitive science of episodic experience still has the most to offer.

Common Misconceptions

Breakthrough pain just means the background pain is not controlled.

By definition, breakthrough pain occurs on a background that is adequately controlled; a flare against uncontrolled baseline pain, or pain returning before the next scheduled dose, is a different problem corrected by adjusting the around-the-clock regimen, not by adding rescue medication (Davies et al., 2009; Mercadante et al., 2002).

A stronger rescue dose is what a bad flare needs.

For a short flare, onset speed matters more than dose: a slow oral tablet acts only after the episode has passed regardless of its strength, whereas a rapid-onset transmucosal opioid covers much of the flare, and its dose must be found by titration rather than scaled from the background regimen (Zeppetella, 2008; Caraceni et al., 2012).

Patients can simply report how bad their flares are.

Retrospective reports of episodic pain are systematically distorted, weighted toward the most intense and most recent moments rather than averaged faithfully, which is why momentary assessment and validated tools are needed to measure a symptom that otherwise lives only in biased memory (Raja et al., 2020; Webber et al., 2014).

Glossary

Background pain.

The persistent, around-the-clock pain against which breakthrough flares occur; breakthrough pain is defined only when this baseline is adequately controlled.

Breakthrough pain.

A transient exacerbation of pain that erupts against a background of otherwise stable, adequately controlled persistent pain, defined by its rapid onset and short duration.

Cancer pain.

Pain arising from a malignancy or its treatment; the setting in which breakthrough pain has been most studied and first defined.

Ecological momentary assessment.

Sampling an experience as it happens in real time, using diaries or electronic prompts, so as to sidestep the reconstruction biases that distort retrospective reports of episodic pain.

End-of-dose failure.

The return of pain before the next scheduled dose of a background analgesic, a sign of an under-dosed regimen usually excluded from breakthrough pain proper.

Episodic pain.

A broader, more neutral umbrella term proposed for transient pain exacerbations, favored by some European groups over the more idiomatic breakthrough pain.

Incident pain.

Breakthrough pain brought on by an identifiable trigger such as movement, coughing, or a procedure; subdivided by how controllable the trigger is.

Onset of relief.

The time from taking a rescue medication to meaningful pain relief; the property that determines how well a drug matches a short flare, and the axis on which rapid-onset opioids are chosen.

Pain catastrophizing.

An exaggerated negative orientation toward actual or anticipated pain, marked by rumination, magnification, and helplessness, whose anticipatory component is amplified by unpredictable flares.

Peak-end rule.

The tendency to remember an experience by its most intense moment and its final moment rather than by its true average, biasing recalled pain away from its actual time course.

Pre-emptive dosing.

Giving a rescue analgesic before a known trigger, so relief coincides with the flare; possible only for predictable volitional incident pain.

Rapid-onset opioid.

An opioid formulation, chiefly transmucosal or intranasal fentanyl, absorbed fast enough to relieve pain within about ten to fifteen minutes, matching the timescale of a flare.

Rescue medication.

A fast-acting analgesic taken on top of the background regimen to treat a breakthrough flare, as distinct from the around-the-clock medication that controls baseline pain.

Spontaneous pain.

Breakthrough pain with no identifiable trigger, also called idiopathic pain; the least predictable subtype and therefore the hardest to manage and the most anxiety-provoking.

Titration.

Finding the effective rescue dose by escalating from a low starting dose, necessary because a patient's rescue requirement cannot be predicted from their background opioid dose.

Transmucosal fentanyl.

A fentanyl preparation absorbed across the lining of the mouth or nose directly into the bloodstream, giving the fast onset that a short flare requires.

Key Researchers

Augusto Caraceni (contemporary). Palliative-care physician at the Istituto Nazionale dei Tumori in Milan and lead author of the European evidence-based recommendations on opioid use in cancer pain. ORCID - Faculty page

Andrew N. Davies (contemporary). Palliative-medicine physician at Trinity College Dublin whose task-group recommendations and monograph shaped the assessment and classification of cancer-related breakthrough pain. Faculty page

Marie Fallon (contemporary). Chair of palliative medicine at the University of Edinburgh and lead author of the ESMO clinical practice guidelines for cancer pain management, including the treatment of breakthrough pain. ORCID - Faculty page - Google Scholar

Stein Kaasa (contemporary). Palliative-medicine researcher at the University of Oslo and director of the European Palliative Care Research Centre, a driving force behind common terminology for transient cancer-pain exacerbations. Faculty page

Sebastiano Mercadante (contemporary). Palliative-care and pain specialist at La Maddalena Cancer Center in Palermo who chaired the European consensus on episodic pain and led the large IOPS-MS survey of breakthrough cancer pain. ORCID - Google Scholar

Russell K. Portenoy (contemporary). Palliative-care physician at the MJHS Institute for Innovation in Palliative Care and Albert Einstein College of Medicine who, with Hagen, coined the modern operational definition of breakthrough pain and established its temporal characteristics. Faculty page

Frequently Asked Questions

What is breakthrough pain? Breakthrough pain is a transient flare of severe pain that erupts against a background of otherwise stable, adequately controlled persistent pain. It is defined by its timing, rising to peak within minutes and typically lasting less than an hour, and it is most studied in cancer patients (Davies et al., 2009).

How is breakthrough pain different from ordinary cancer pain? Ordinary background pain is steady and controlled by an around-the-clock regimen; breakthrough pain is a sudden flare on top of that controlled baseline. The distinction matters because the two are treated differently, one by adjusting the baseline regimen and the other by adding a fast rescue dose (Portenoy et al., 1999).

What are the main types of breakthrough pain? The primary division is between incident pain, triggered by an identifiable event such as movement, and spontaneous pain, which arrives without warning. Incident pain further divides by how controllable the trigger is, which determines whether it can be pre-empted (Haugen et al., 2010).

Why does regular oral pain medication not work well for flares? An immediate-release oral opioid takes about thirty minutes or more to relieve pain, by which time a typical flare has already peaked and subsided. Its onset is simply too slow to match the short time course of breakthrough pain (Zeppetella, 2008).

What medications are used for breakthrough pain? Rapid-onset opioids, chiefly transmucosal and intranasal fentanyl, are the treatment of choice because they act within about ten to fifteen minutes, matching the flare. Their dose is found by titration rather than scaled from the background regimen (Zeppetella & Davies, 2013; Caraceni et al., 2012).

Why is breakthrough pain so hard to measure? Because a flare is brief and usually over before a patient reaches a clinic, most information about it comes from memory, and memory for pain is biased toward the most intense and most recent moments. Momentary assessment and validated tools are used to reduce this distortion (Raja et al., 2020; Webber et al., 2014).

How common is breakthrough pain? Estimates vary widely with how it is defined, but a pooled analysis of the cancer literature put the average prevalence among patients with pain at around 60%, with individual studies ranging from roughly 40% to 80% (Deandrea et al., 2014).

Why is breakthrough pain called episodic pain by some researchers? The term breakthrough pain does not translate cleanly across languages and overlaps imperfectly with related terms. A European expert survey favored episodic pain as a broader, more neutral umbrella term in the search for a common terminology (Løhre et al., 2016).

References